Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Richard A. Burkhart

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1618-4006; OpenAlex author ID A5101669616. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: 4 papers · 2026: 1 paper

Papers 10

  1. Patient-derived Organoid Pharmacotyping as a Predictive Tool for Therapeutic Selection in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/sla.0000000000006517↗
  2. Therapeutic Targeting of Oncogene-Induced Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.02.038↗
  3. The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Su… Co-author DOI 10.1097/sla.0000000000006794↗
  4. Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. Co-author DOI 10.1200/po-24-00494↗
  5. Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17439-x↗
  6. Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review. First author DOI 10.1093/bjsopen/zrad023↗
  7. Persistent Circulating Tumor Cells at 1 Year After Oncologic Resection Predict Late Recurrence in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005708↗
  8. An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-… Last author DOI 10.1245/s10434-020-09201-2↗
  9. Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-019-04311-z↗
  10. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2020.06.019↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 6 shared papers, 2020–2026 · strength 1.00
  2. Kelly J. Lafaro · 4 shared papers, 2021–2026 · strength 0.80
  3. Toni T. Seppälä · 3 shared papers, 2023–2026 · strength 0.75
  4. William Reece Burns · 3 shared papers, 2025–2026 · strength 0.68
  5. Christopher Lee Wolfgang · 4 shared papers, 2020–2025 · strength 0.64
  6. Ammar A. Javed · 4 shared papers, 2020–2025 · strength 0.64
  7. Christopher R. Shubert · 2 shared papers, 2025–2026 · strength 0.45
  8. Brady A. Campbell · 2 shared papers, 2025 · strength 0.44
  9. Ding Ding · 3 shared papers, 2020–2023 · strength 0.41
  10. Michael Goggins · 2 shared papers, 2020–2025 · strength 0.32
  11. Daniel A. Laheru · 2 shared papers, 2020–2025 · strength 0.32
  12. Bryson W. Katona · 1 shared paper, 2023 · strength 0.31
  13. Lei Zheng · 2 shared papers, 2020–2023 · strength 0.29
  14. Elana Judith Fertig · 1 shared paper, 2026 · strength 0.24
  15. Samantha R. Guinn · 1 shared paper, 2026 · strength 0.24
  16. Norman G. Nicolson · 1 shared paper, 2026 · strength 0.24
  17. Elizabeth M. Jaffee · 1 shared paper, 2026 · strength 0.24
  18. Jacquelyn W. Zimmerman · 1 shared paper, 2026 · strength 0.24
  19. Lois A. Daamen · 1 shared paper, 2025 · strength 0.23
  20. Izaak Quintus Molenaar · 1 shared paper, 2025 · strength 0.23
  21. Joseph R. Habib · 1 shared paper, 2025 · strength 0.23
  22. Paul C. M. Andel · 1 shared paper, 2025 · strength 0.23
  23. William R. Burns · 2 shared papers, 2020–2021 · strength 0.23
  24. Michael J. Wright · 2 shared papers, 2020–2021 · strength 0.23
  25. Amanda L. Blackford · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.